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ABSTRACT
Lung cancer is the most common cause of cancer-
related mortality with more than 1.4 million deaths
per year worldwide. To search for significant
somatic alterations in lung cancer, we analyzed,
integrated and manually curated various data sets
and literatures to present an integrated genomic
database of non-small cell lung cancer
(IGDB.NSCLC, http://igdb.nsclc.ibms.sinica.edu.tw).
We collected data sets derived from hundreds of
human NSCLC (lung adenocarcinomas and/or
squamous cell carcinomas) to illustrate genomic
alterations [chromosomal regions with copy
number alterations (CNAs), gain/loss and loss of
heterozygosity], aberrant expressed genes and
microRNAs, somatic mutations and experimental
evidence and clinical information of alterations
retrieved from literatures. IGDB.NSCLC provides
user friendly interfaces and searching functions to
display multiple layers of evidence especially
emphasizing on concordant alterations of CNAs
with co-localized altered gene expression, aberrant
microRNAs expression, somatic mutations or genes
with associated clinicopathological features. These
significant concordant alterations in NSCLC are
graphically or tabularly presented to facilitate and
prioritize as the putative cancer targets for patho-
logical and mechanistic studies of lung tumorigen-
esis and for developing new strategies in clinical
interventions.
INTRODUCTION
Cancer is the leading killer of human beings with more
than 7.4 million deaths worldwide per year. Among them,
lung cancer is the most common cause of cancer-related
mortality in both men and women with over 1.4 million
deaths annually (1). Lung cancer can be divided into two
categories: small cell lung cancer (SCLC) and non-small
cell lung cancer (NSCLC). Approximately 85% of total
lung cancers are NSCLC that can be further classiﬁed into
two major subtypes: squamous cell carcinoma (SCC) and
adenocarcinoma (AD). Recent remarkable advances in
identiﬁcation of genetic alterations including p53, KRAS,
EGFR, HER2, c-MET, LKB1, PIK3CA, BRAF and
EML4-ALK not only provided mechanistic understanding
of tumor growth and metastatic advantages but also
served as targets for diagnosis and therapy (2–12).
Moreover, a recent report suggested that high risk lung
cancer individuals aged 55–74 years with heavy smoking
history is associated with a 20% reduction in lung cancer
mortality when computed tomography (CT) lung cancer
screening is conducted in comparison with chest X-ray
screening (http://www.cancer.gov/images/dsmb-nlst.pdf).
Even with these recent advances, early screening of lung
cancer is still inconsistent and the overall 5-year survival
rate of lung cancer remains around 15% (13–15).
Therefore, discovery of altered genes for early detection
and as therapeutic targets is urgently needed to prolong
the life of lung cancer patients.
Similar to many other cancers, lung cancer is a complex
and heterogeneous genetic disease resulting from the ac-
cumulation of genetic and epigenetic alterations during
multiple steps of tumor progression and metastasis
(16,17). Depending on tumor subtype, ethnicity, gender
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asbestos and cooking oil fumes), accumulated alterations
exploit different tumorigenic mechanisms resulting in
aberrant activation of oncogenic signaling pathways and
uncontrolled tumor growth and metastasis (18–20). To
identify common cancer-associated alterations, applica-
tion of high-throughput genomic technologies including
DNA sequencing and high density microarrays allowed
investigators to generate comprehensive genome-wide
data sets of somatic mutations, copy number alterations
(CNAs), transcriptomics and altered microRNA
(miRNAs) expression of lung cancer genomes (21–33).
In combination with clinical features, investigators were
able to independently identiﬁed proﬁles from these
genomic alterations for categorization of lung cancer
subtypes, identiﬁcation of cancer genes for tumorigenic
studies, diagnostic and prognostic prediction of patient
outcomes and development of various strategies to
improve patient care.
To facilitate identiﬁcation of common alterations that
might embrace oncogenic or tumor suppressive genes in
NSCLC, we curated numerous genomic data sets and
established the integrated database IGDB.NSCLC. We
graphically displayed multiple dimensional data of lung
cancer somatic alterations including somatic mutations,
CNAs, aberrant expression of genes and miRNAs,
chromosomal gain and loss regions, frequent loss of het-
erozygosity (LOH) regions and experimental supports of
alterations retrieved from lung cancer literatures. Altered
gene expression in association with clinicopathological
features and patient outcomes is also included for develop-
ing biomarkers in clinical managements. Although lung
cancer is the most common cause of cancer-related mor-
tality with rapid expansion of cancer genomic studies,
limited efforts were made to integrate these genomic
resources for a coherent and user-friendly presentation.
A database HLungDB was reported as a helpful
resource of human lung cancer research with integrated
and networking analysis of lung cancer-related genes,
proteins and miRNAs extracted manually from literatures
(34). However, IGDB.NSCLC provides not only lung
cancer genes and miRNAs from published reports but
also analyzed various lung cancer genomic data sets for
simultaneous illustrations of somatic alterations at
genome, RNA, protein, function and application levels.
The simultaneous illustrations provide multiple layers of
evidence for investigators to detect and prioritize the
common altered genes and miRNAs accessible to the sci-
entiﬁc and medical communities. Moreover, we speciﬁc-
ally emphasized on concordant alterations in altered
NSCLC cancer genomes such as (i) up-regulated genes
and miRNAs encoded in regions of genomic ampliﬁca-
tion; (ii) down-regulated genes and miRNAs encoded in
regions of genomic deletion; (iii) mutation genes with
concordant genomic alterations; and (iv) genes with sig-
niﬁcant association with clinical information encoded in
regions of genomic alterations. These altered genes deﬁned
as signiﬁcant genes and miRNAs in NSCLC were graph-
ically and tabularly displayed in IGDB.NSCLC and
should be prioritized to develop as useful targets for
improvement of patient management.
DATABASE CONSTRUCTION
For integration of various genomic resources of NSCLC,
we collected genomic data generated from primary tissue
samples of lung AD and SCC separately (Supplementary
Table S1). For altered gene expression performed in
microarrays, we collected 15 data sets from 1099 AD,
295 SCC and 189 normal tissue samples from ﬁve different
microarray platforms. An expression proﬁling data set
(GSE14814) of 90 NSCLC samples with and without cis-
platin/vinorelbine treatment was included for revealing
potential prognostic markers in NSCLC (35). We also
included a reported pair data set of 193 lung AD
samples with genomic alteration performed in 44K
Agilent CGH array and expression alteration in
Affymetrix U133A and U133 2.0 arrays for concordant
alterations from the same samples (36).
For processing Affymetrix gene expression data sets, the
raw data (CEL ﬁles) were normalized by MAS 5.0 (an affy
package from Bioconductor/R at http://www
.bioconductor.org/packages/release/bioc/html/affy.html)
(37). Quality control (QC) results were performed by the
simpleaffy and affyQCReport packages (http://www
.bioconductor.org/packages/release/bioc/html/
affyQCReport.html and http://www.bioconductor.org/
packages/release/bioc/html/simpleaffy.html) with three
stringent QC criteria for inclusion of a microarray data:
(i) the scaling factor of a given sample should be within
two standard deviations of mean of the same array
platform, (ii) the present calls of a given sample should
be >25% and (iii) the 30/50 GAPDH ratios of a given
sample should be <3( 38). After these QC process, 46
samples were eliminated (HG_U95A: 22 samples,
HG-U133A: 2 samples and HG-U133_Plus_2: 22
samples). The data sets from the same platform were
normalized using the normalize.quantiles in R. Finally,
all probeset intensity value was transformed to log2
value. For data performed in two color microarrays
(Agilent and Stanford data sets), expression proﬁles were
downloaded form GEO website directly. The log10 ratio
of the Agilent data set was transformed to log2 ratio. The
differential expression genes for each platform were
ranked on moderated t-statistics and selected with
P<0.01 under the Bayesian adjusted t-statistics from the
linear models for microarray data (limma) package (39).
For detection of CNAs, we downloaded three data sets
of 191 AD, 117 SCC and 271 normal tissue samples per-
formed in Affymetrix GeneChip single nucleotide poly-
morphism (SNP) arrays and analyzed by dChip software
(40). In brief, CEL format data are normalized using
invariant set normalization algorithms and then
normalized-within-chip intensity data are generated
based on the reference data set of 50 normal individuals
genotyped in the same platform. Based on these signal
values, the raw copy number for an SNP in a sample is
computed as: [log2(intensity of SNP/mean of intensity of
reference 2)]. A window size of three SNPs is then
applied for median smoothing method and to infer raw
copy number (ICN) (41). We deﬁned the ampliﬁed regions
with ICN more than three and deleted regions with ICN
less than one (42). For altered expression of miRNAs,
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collected and the miRNAs expression was analyzed by
calculating the mean (±standard deviation) of the log2
ratios of tumor/non-tumor adjacent tissues. For analysis
of arrayed comparative genome hybridization (aCGH)
data, we obtained two data sets of 70 SCC tissue
samples and analyzed them using the cghMCR package
(http://www.bioconductor.org/packages/2.4/bioc/html/
cghMCR.html). The gain and loss regions were calculated
based on the SGOL (Segment Gain Or Loss) scores by
calculating the summations of all the positive values
over a threshold of copy number (CN) >3 and all the
negative values below a threshold of CN<1.2, respect-
ively. In addition, we also integrated at least 1112
somatic mutation genes of NSCLC from COSMIC and
literatures, 214 lung cancer genes with experimental
evidence, 131 genes with association with clinico-
pathological features of NSCLC and other genomic alter-
ations such as LOH and minimum region of alterations
from literatures and our unpublished data.
RESULTS
Multiple levels of somatic alterations in NSCLC
To facilitate identiﬁcation of cancer-associated somatic
altered genes, we aimed to provide lines of evidence for
investigators to prioritize these genes for mechanistic
studies and clinical applications in NSCLC. The
integrated framework of IGDB.NSCLC is constructed
based on the physical map of human genome sequence
from Ensembl with various integrated somatic alterations
alongside (Figure 1). Users could apply various searching
terms (gene, marker, cytogentic location and other key
words) for displaying the altered data in lung AD, SCC
and/or combined NSCLC. Three major illustrations
including chromosome view, gene view and miRNA
view are provided for simultaneous displays of concordant
alterations in the same interface. In the chromosome view,
the interface demonstrated the comprehensive and
integrated alterations in relation to NSCLC genes and
regions including evidence of experimental support,
somatic mutation, altered gene expression, CNAs, LOH
and other chromosomal alterations. We provided ERBB2,
EGFR and MET as tutorial examples (please see our
quick examples of chromosome view). In gene view, we
presented the details of aberrant information of the
selected gene including (i) mutation frequency and
details of mutation changes; (ii) frequency of altered
gene expression supported by experimental evidence such
as immunohistochemistry (IHC), RT–PCR or western
blot analysis and in association with clinical information;
(iii) the fold changes and the statistic signiﬁcance of
altered expression of each probe set in a selected gene
from a given microarray platform; (iv) the distribution
plots of the altered expressing gene in a set of multiple
NSCLC tissues shown in log2 ratios of tumor/
non-tumor adjacent tissues; and (v) the publication
status of the aberrant gene in various cancers provided
in the cancer gene index and the literature (see our quick
examples of gene view). In miRNA view, we also provided
details of the aberrant expression of a miRNA as similar
to that of gene view in addition to external links for
predicting miRNA target genes in MICROCOSM (43),
TARGETSCAN (44), PICTAR-VERT (45) and
miRTarBase (46). We provided three miRNAs including
hsa-let-7e, hsa-mir-17 and hsa-mir-31 as tutorial examples
(see our quick examples of miRNA view).
Concordant somatic alterations in NSCLC
To further reveal signiﬁcant cancer-associated genes and
miRNAs involved in tumor progression of NSCLC, we
applied CNA (ampliﬁcation: Inferred copy number ICN
>3 and deletion: ICN <1) as the framework and searched
for concordant existence of (i) genes with altered expres-
sion, (ii) miRNA with altered expression, (iii) genes with
common somatic mutations and (iv) genes associated with
clinicopathological features from literatures. For genes
with altered expression existing in regions of CNA, we
found 27 up-regulated genes located in ampliﬁed regions
and seven down-regulated genes residing in deleted
regions in AD; and 23 up-regulated genes in ampliﬁed
regions and 13 down-regulated genes in deleted regions
in SCC (Figure 2 and Supplementary Table S2). Some
of these genes were previously identiﬁed as altered expres-
sion genes in NSCLC for validation but majority of these
genes remain unknown in the tumorigenesis of NSCLC.
For miRNAs with altered expression residing in CNA
regions, we identiﬁed 21 up-regulated miRNAs located
in the ampliﬁed regions and 19 down-regulated miRNAs
in the deleted regions in AD, and 19 up-regulated
miRNAs in the ampliﬁed regions and 20 down-regulated
miRNAs in the deleted regions in SCC (Supplementary
Figure S1 and Supplementary Table S3). Similarly, we
found that some of these aberrant miRNAs were validated
by previous reports but majority of them are novel signiﬁ-
cant miRNAs in the tumor formation of NSCLC.
We also examined the concordance of genes with
common somatic mutations (at least mutations in ﬁve
cases) that resides in the CNA regions of NSCLC. A
total of 1112 genes with somatic mutations including 386
in AD and 55 in SCC were downloaded from COSMIC
database (47). Majority of these somatic mutations
occurred only once in NSCLC tissues except 43 genes in
AD and seven genes in SCC conferred at least ﬁve inde-
pendent somatic mutations. Interestingly, majority of
these common mutated genes including 33/43 (76.7%) in
AD and 6/7 (85.7%) in SCC are co-localized with CNA
regions in NSCLC (Table 1). Our results further
demonstrated that genes with frequent somatic mutations
are commonly afﬁliated with chromosomal alterations
involved in the tumorigenesis of NSCLC.
To further examine the link between clinicopathological
features with somatic alterations, we collected 309 papers
with 125 genes in AD and 105 genes in SCC validated by
experimental evidence such as IHC, RT–PCR and western
analysis for conﬁrmation of altered expression in NSCLC.
Among them, 62 (62/125, 49.6%) genes in AD and 54
(54/105, 51.4%) genes in SCC extracted from 159 papers
were shown to associate with 22 clinicopathological
features and to be located in the CNA regions
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Figure 1. The framework of IGDB.NSCLC.
Nucleic Acids Research, 2012,Vol.40, Database issue D975(Supplementary Table S4). Our results suggested that
NSCLC genes associated with clinicopathological
features commonly ( 50%) reside in the CNA regions,
reﬂecting the genetic effects participated in pathological
changes of tumor formation in NSCLC.
DISCUSSION
As far as we know, IGDB.NSCLC is the largest integra-
tion of lung cancer genomic resources providing multiple
levels of evidence to search for the concordantly altered
targets and to prioritize putative NSCLC genes for future
studies. In addition to the database with various searching
options and user-friendly interfaces, we provided concord-
ant somatic alterations based on the genome-wide CNAs
data with co-localization of altered gene expression,
aberrant miRNA expression, somatic mutation and
genes in association with clinicopathological features.
The high concordance of CNA data with these somatic
alterations and clinical features in IGDB.NSCLC sug-
gested the quality of data integration with experimental
validations, the heterogeneity of genetic pathways to
NSCLC and the important roles of genomic alterations
involved in tumor formation of NSCLC. The future de-
velopment of integrating other NSCLC resources into
IGDB.NSCLC will focus on increasing the data of
clinicopathological features for dissecting the altered
genes involved in tumor progression and on somatic alter-
ation data from next-generation sequencing results. In
conclusion, IGDB.NSCLC is an invaluable resource for
selecting putative cancer genes in NSCLC to better under-
stand the heterogeneous tumorigenic mechanisms and for
developing useful strategies in clinical applications to
prolong the life of lung cancer patients.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Tables 1–4, Supplementary Figure 1.
ACKNOWLEDGEMENTS
The following authors contributed toward this study:
database construction: S.K. and C.K.S.; data analysis
and interpretation: S.K., D.L.G., C.M.H. and C.F.C.;
drafting of the manuscript and study supervision:
W.H.S., C.F.C., C.H.L. and Y.S.J.
FUNDING
National Research Program for Genomic Medicine
(NSC98-3112-B-001-004, NSC98-3112-B-001-031);
National Research Program for Biopharmaceuticals,
National Science Council, Taiwan (NSC100-2325-B-001-
012). Funding for open access charge: Institute of
Biomedical Sciences, Academia Sinica, Taiwan.
Conﬂict of interest statement. None declared.
REFERENCES
1. WHO. World Health Organization. ‘‘Cancer’’. http://www.who
.int/mediacentre/factsheets/fs297/en/. (3 March 2010, date last
accessed).
2. Brose,M.S., Volpe,P., Feldman,M., Kumar,M., Rishi,I.,
Gerrero,R., Einhorn,E., Herlyn,M., Minna,J., Nicholson,A. et al.
(2002) BRAF and RAS mutations in human lung cancer and
melanoma. Cancer Res., 62, 6997–7000.
3. Lynch,T.J., Bell,D.W., Sordella,R., Gurubhagavatula,S.,
Okimoto,R.A., Brannigan,B.W., Harris,P.L., Haserlat,S.M.,
Supko,J.G., Haluska,F.G. et al. (2004) Activating mutations in
the epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to geﬁtinib. N. Engl. J. Med., 350,
2129–2139.
4. Ma,P.C., Jagadeeswaran,R., Jagadeesh,S., Tretiakova,M.S.,
Nallasura,V., Fox,E.A., Hansen,M., Schaefer,E., Naoki,K.,
Lader,A. et al. (2005) Functional expression and mutations of
c-Met and its therapeutic inhibition with SU11274 and small
interfering RNA in non-small cell lung cancer. Cancer Res., 65,
1479–1488.
5. Naoki,K., Chen,T.H., Richards,W.G., Sugarbaker,D.J. and
Meyerson,M. (2002) Missense mutations of the BRAF gene in
human lung adenocarcinoma. Cancer Res., 62, 7001–7003.
6. Paez,J.G., Janne,P.A., Lee,J.C., Tracy,S., Greulich,H., Gabriel,S.,
Herman,P., Kaye,F.J., Lindeman,N., Boggon,T.J. et al. (2004)
EGFR mutations in lung cancer: correlation with clinical
response to geﬁtinib therapy. Science, 304, 1497–1500.
7. Samuels,Y. and Velculescu,V.E. (2004) Oncogenic mutations of
PIK3CA in human cancers. Cell Cycle, 3, 1221–1224.
8. Samuels,Y., Wang,Z., Bardelli,A., Silliman,N., Ptak,J., Szabo,S.,
Yan,H., Gazdar,A., Powell,S.M., Riggins,G.J. et al. (2004) High
frequency of mutations of the PIK3CA gene in human cancers.
Science, 304, 554.
9. Sanchez-Cespedes,M., Parrella,P., Esteller,M., Nomoto,S.,
Trink,B., Engles,J.M., Westra,W.H., Herman,J.G. and
Sidransky,D. (2002) Inactivation of LKB1/STK11 is a common
event in adenocarcinomas of the lung. Cancer Res., 62,
3659–3662.
10. Santos,E., Martin-Zanca,D., Reddy,E.P., Pierotti,M.A., Della
Porta,G. and Barbacid,M. (1984) Malignant activation of a K-ras
oncogene in lung carcinoma but not in normal tissue of the same
patient. Science, 223, 661–664.
11. Stephens,P., Hunter,C., Bignell,G., Edkins,S., Davies,H.,
Teague,J., Stevens,C., O’Meara,S., Smith,R., Parker,A. et al.
Table 1. Common mutated genes in copy number alteration regions of NSCLC
Non-small cell
lung carcinoma
Alteration Genes with at least ﬁve somatic mutations
AD Mutated genes in ampliﬁed regions (30 genes) APC, BRAF, CDC42BPA, CDKN2A, CTNNB1, EGFR, EPHA3, EPHA5,
EPHA7, EPHB6, FGFR4, FLT1, INSRR, JAK2, KDR, KIAA1804,
KRAS, LMTK2, MET, NRAS, NTRK1, PAK7, PDGFRA, PIK3C3,
PIK3CA, PIK3CG, PRKDC, RB1, ROBO2, TERT
Mutated genes in deleted regions NOTCH1, PTEN, TP53
SCC Mutated genes in ampliﬁed regions BRAF, CDKN2A, EGFR, KRAS, PIK3CA
Mutated genes in deleted regions TP53
D976 Nucleic AcidsResearch, 2012, Vol.40,Database issue(2004) Lung cancer: intragenic ERBB2 kinase mutations in
tumours. Nature, 431, 525–526.
12. Takahashi,T., Nau,M.M., Chiba,I., Birrer,M.J., Rosenberg,R.K.,
Vinocour,M., Levitt,M., Pass,H., Gazdar,A.F. and Minna,J.D.
(1989) p53: a frequent target for genetic abnormalities in lung
cancer. Science, 246, 491–494.
13. Bach,P.B. (2011) Inconsistencies in ﬁndings from the early
lung cancer action project studies of lung cancer screening.
J. Natl. Cancer Inst., 103, 1002–1006.
14. Van’t Westeinde,S.C. and van Klaveren,R.J. (2011) Screening and
early detection of lung cancer. Cancer J., 17, 3–10.
15. Jemal,A., Siegel,R., Ward,E., Hao,Y., Xu,J. and Thun,M.J.
(2009) Cancer statistics, 2009. CA Cancer J. Clin., 59, 225–249.
16. Agullo-Ortuno,M.T., Lopez-Rios,F. and Paz-Ares,L. (2010)
Lung cancer genomic signatures. J. Thorac. Oncol., 5, 1673–1691.
17. Risch,A. and Plass,C. (2008) Lung cancer epigenetics and
genetics. Int. J. Cancer, 123, 1–7.
18. Chaffer,C.L. and Weinberg,R.A. (2011) A perspective on cancer
cell metastasis. Science, 331, 1559–1564.
19. Hanahan,D. and Weinberg,R.A. (2011) Hallmarks of cancer:
the next generation. Cell, 144, 646–674.
20. Sun,S., Schiller,J.H. and Gazdar,A.F. (2007) Lung cancer in
never smokers—a different disease. Nat. Rev. Cancer, 7, 778–790.
21. Puissegur,M.P., Mazure,N.M., Bertero,T., Pradelli,L., Grosso,S.,
Robbe-Sermesant,K., Maurin,T., Lebrigand,K., Cardinaud,B.,
Hofman,V. et al. (2011) miR-210 is overexpressed in late stages
of lung cancer and mediates mitochondrial alterations associated
with modulation of HIF-1 activity. Cell Death Differ., 18,
465–478.
22. Landi,M.T., Zhao,Y., Rotunno,M., Koshiol,J., Liu,H.,
Bergen,A.W., Rubagotti,M., Goldstein,A.M., Linnoila,I.,
Marincola,F.M. et al. (2010) MicroRNA expression differentiates
histology and predicts survival of lung cancer. Clin. Cancer Res.,
16, 430–441.
23. Bass,A.J., Watanabe,H., Mermel,C.H., Yu,S., Perner,S.,
Verhaak,R.G., Kim,S.Y., Wardwell,L., Tamayo,P., Gat-Viks,I.
et al. (2009) SOX2 is an ampliﬁed lineage-survival oncogene in
lung and esophageal squamous cell carcinomas. Nat. Genet., 41,
1238–1242.
24. Boelens,M.C., Kok,K., van der Vlies,P., van der Vries,G.,
Sietsma,H., Timens,W., Postma,D.S., Groen,H.J. and van den
Berg,A. (2009) Genomic aberrations in squamous cell lung
carcinoma related to lymph node or distant metastasis. Lung
Cancer, 66, 372–378.
25. Broet,P., Camilleri-Broet,S., Zhang,S., Alifano,M.,
Bangarusamy,D., Battistella,M., Wu,Y., Tuefferd,M.,
Regnard,J.F., Lim,E. et al. (2009) Prediction of clinical outcome
in multiple lung cancer cohorts by integrative genomics:
implications for chemotherapy selection. Cancer Res., 69,
1055–1062.
26. Ding,L., Getz,G., Wheeler,D.A., Mardis,E.R., McLellan,M.D.,
Cibulskis,K., Sougnez,C., Greulich,H., Muzny,D.M.,
Morgan,M.B. et al. (2008) Somatic mutations affect key pathways
in lung adenocarcinoma. Nature, 455, 1069–1075.
27. Shedden,K., Taylor,J.M., Enkemann,S.A., Tsao,M.S.,
Yeatman,T.J., Gerald,W.L., Eschrich,S., Jurisica,I., Giordano,T.J.,
Misek,D.E. et al. (2008) Gene expression-based survival
prediction in lung adenocarcinoma: a multi-site, blinded
validation study. Nat. Med., 14, 822–827.
28. Weir,B.A., Woo,M.S., Getz,G., Perner,S., Ding,L., Beroukhim,R.,
Lin,W.M., Province,M.A., Kraja,A., Johnson,L.A. et al. (2007)
Characterizing the cancer genome in lung adenocarcinoma.
Nature, 450, 893–898.
29. Raponi,M., Zhang,Y., Yu,J., Chen,G., Lee,G., Taylor,J.M.,
Macdonald,J., Thomas,D., Moskaluk,C., Wang,Y. et al. (2006)
Gene expression signatures for predicting prognosis of squamous
cell and adenocarcinomas of the lung. Cancer Res., 66,
7466–7472.
30. Takeuchi,T., Tomida,S., Yatabe,Y., Kosaka,T., Osada,H.,
Yanagisawa,K., Mitsudomi,T. and Takahashi,T. (2006)
Expression proﬁle-deﬁned classiﬁcation of lung adenocarcinoma
shows close relationship with underlying major genetic changes
and clinicopathologic behaviors. J. Clin. Oncol., 24, 1679–1688.
31. Tseng,R.C., Chang,J.W., Hsien,F.J., Chang,Y.H., Hsiao,C.F.,
Chen,J.T., Chen,C.Y., Jou,Y.S. and Wang,Y.C. (2005)
Genomewide loss of heterozygosity and its clinical associations in
non small cell lung cancer. Int. J. Cancer, 117, 241–247.
32. Garber,M.E., Troyanskaya,O.G., Schluens,K., Petersen,S.,
Thaesler,Z., Pacyna-Gengelbach,M., van de Rijn,M., Rosen,G.D.,
Perou,C.M., Whyte,R.I. et al. (2001) Diversity of gene expression
in adenocarcinoma of the lung. Proc. Natl. Acad. Sci. USA, 98,
13784–13789.
33. Bhattacharjee,A., Richards,W.G., Staunton,J., Li,C., Monti,S.,
Vasa,P., Ladd,C., Beheshti,J., Bueno,R., Gillette,M. et al. (2001)
Classiﬁcation of human lung carcinomas by mRNA expression
proﬁling reveals distinct adenocarcinoma subclasses. Proc. Natl.
Acad. Sci. USA, 98, 13790–13795.
34. Wang,L., Xiong,Y., Sun,Y., Fang,Z., Li,L., Ji,H. and Shi,T.
(2010) HLungDB: an integrated database of human lung cancer
research. Nucleic Acids Res., 38, D665–D669.
35. Zhu,C.Q., Ding,K., Strumpf,D., Weir,B.A., Meyerson,M.,
Pennell,N., Thomas,R.K., Naoki,K., Ladd-Acosta,C., Liu,N.
et al. (2010) Prognostic and predictive gene signature for adjuvant
chemotherapy in resected non-small-cell lung cancer. J. Clin.
Oncol., 28, 4417–4424.
36. Chitale,D., Gong,Y., Taylor,B.S., Broderick,S., Brennan,C.,
Somwar,R., Golas,B., Wang,L., Motoi,N., Szoke,J. et al. (2009)
An integrated genomic analysis of lung cancer reveals loss of
DUSP4 in EGFR-mutant tumors. Oncogene, 28, 2773–2783.
37. Gautier,L., Cope,L., Bolstad,B.M. and Irizarry,R.A. (2004)
affy—analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics, 20, 307–315.
38. Tumor Analysis Best Practices Working Group (2004) Expression
proﬁling—best practices for data generation and interpretation in
clinical trials. Nat. Rev. Genet, 5, 229–237.
39. Wettenhall,J.M. and Smyth,G.K. (2004) limmaGUI: a graphical
user interface for linear modeling of microarray data.
Bioinformatics, 20, 3705–3706.
40. Li,C. and Wong,W.H. (2001) Model-based analysis of
oligonucleotide arrays: expression index computation and outlier
detection. Proc. Natl. Acad. Sci. USA, 98, 31–36.
41. Shiau,C.K., Gu,D.L., Chen,C.F., Lin,C.H. and Jou,Y.S. (2011)
IGRhCellID: integrated genomic resources of human cell lines for
identiﬁcation. Nucleic Acids Res., 39, D520–D524.
42. Chen,C.F., Hsu,E.C., Lin,K.T., Tu,P.H., Chang,H.W., Lin,C.H.,
Chen,Y.J., Gu,D.L., Wu,J.Y., Chen,Y.T. et al. (2010)
Overlapping high-resolution copy number alterations in cancer
genomes identiﬁed putative cancer genes in hepatocellular
carcinoma. Hepatology, 52, 1690–1701.
43. Grifﬁths-Jones,S., Saini,H.K., van Dongen,S. and Enright,A.J.
(2008) miRBase: tools for microRNA genomics. Nucleic Acids
Res., 36, D154–D158.
44. Lewis,B.P., Burge,C.B. and Bartel,D.P. (2005) Conserved seed
pairing, often ﬂanked by adenosines, indicates that thousands of
human genes are microRNA targets. Cell, 120, 15–20.
45. Krek,A., Grun,D., Poy,M.N., Wolf,R., Rosenberg,L.,
Epstein,E.J., MacMenamin,P., da Piedade,I., Gunsalus,K.C.,
Stoffel,M. et al. (2005) Combinatorial microRNA target
predictions. Nat. Genet., 37, 495–500.
46. Sethupathy,P., Corda,B. and Hatzigeorgiou,A.G. (2006) TarBase:
A comprehensive database of experimentally supported animal
microRNA targets. RNA, 12, 192–197.
47. Forbes,S.A., Tang,G., Bindal,N., Bamford,S., Dawson,E.,
Cole,C., Kok,C.Y., Jia,M., Ewing,R., Menzies,A. et al. (2010)
COSMIC (the Catalogue of Somatic Mutations in Cancer): a
resource to investigate acquired mutations in human cancer.
Nucleic Acids Res., 38, D652–D657.
Nucleic Acids Research, 2012,Vol.40, Database issue D977